NCT05150457 - Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2025

Conditions

Refractory Solid Tumors

Interventions

DRUG

BNA035

Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody

Trial Locations (3)

RECRUITING

St George Private Hospital, Kogarah

RECRUITING

St. Vincents Hospital Melbourne, Fitzroy

RECRUITING

Pindara Private Hospital, Benowa